Yamazaki, H.; Suzuki, G.; Masui, K.; Aibe, N.; Shimizu, D.; Kimoto, T.; Yoshida, K.; Nakamura, S.; Okabe, H.
Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy. Cancers 2021, 13, 1856.
https://doi.org/10.3390/cancers13081856
AMA Style
Yamazaki H, Suzuki G, Masui K, Aibe N, Shimizu D, Kimoto T, Yoshida K, Nakamura S, Okabe H.
Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy. Cancers. 2021; 13(8):1856.
https://doi.org/10.3390/cancers13081856
Chicago/Turabian Style
Yamazaki, Hideya, Gen Suzuki, Koji Masui, Norihiro Aibe, Daisuke Shimizu, Takuya Kimoto, Ken Yoshida, Satoaki Nakamura, and Haruumi Okabe.
2021. "Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy" Cancers 13, no. 8: 1856.
https://doi.org/10.3390/cancers13081856
APA Style
Yamazaki, H., Suzuki, G., Masui, K., Aibe, N., Shimizu, D., Kimoto, T., Yoshida, K., Nakamura, S., & Okabe, H.
(2021). Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy. Cancers, 13(8), 1856.
https://doi.org/10.3390/cancers13081856